Physician profile
Karin Brooks
NPI 1083638977
$903.60
in general payments reported to CMS, 2019-2025
16 companies · $576 in 2025
The $576 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $327 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $141.01 | 2024-2025 | Zoryve |
| Abbvie INC. | $134.87 | 2024-2025 | |
| Lilly USA, LLC | $91.43 | 2024-2025 | Taltz, Ebglyss |
| Janssen Biotech, INC. | $76.29 | 2025 | Tremfya |
| Genzyme Corporation | $68.49 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $60.73 | 2024-2025 | Jublia, Cabtreo, Arazlo |
| Ucb, INC. | $56.01 | 2024-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $45.82 | 2024-2025 | |
| Organon LLC | $39.69 | 2025 | Vtama |
| Amgen INC. | $37.35 | 2025 | Otezla |
| Leo Pharma INC. | $33.24 | 2024 | Adbry |
| Incyte Corporation | $28.72 | 2025 | Opzelura |
| Revance Therapeutics, INC. | $25.00 | 2024 | Daxxify |
| Galderma Laboratories, L.P. | $24.52 | 2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $21.52 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $18.91 | 2025 | Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.